3,6-DMAD hydrochloride|西域试剂

3,6-DMAD hydrochloride,99.0%

产品编号：Bellancom-U00460| 分子式：C₂₂H₃₁N₅

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-U00460		￥3600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

3,6-DMAD hydrochloride

产品介绍

3,6-DMAD hydrochloride 是一种吖啶衍生物，是一种有效的 IRE1α-XBP1s 通路抑制剂。 3,6-DMAD hydrochloride 通过 IRE1α-XBP1s 通路促进 IL-6 分泌。3,6-DMAD hydrochloride 可抑制 IRE1α 寡聚化和核糖核酸内切酶 (RNase) 活性。3,6-DMAD hydrochloride 可用于癌症的研究。

生物活性

3,6-DMAD hydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD hydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD hydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD hydrochloride can be used for research of cancer.

体外研究

3,6-DMAD hydrochloride (0-6 μM; 24 h; RPMI 8226 and MM1.R human MM cells) has cytotoxicity against MM cell lines.
3,6-DMAD hydrochloride (0-30 μM; 14 h; HT1080 cells treated with Tg (0.3 μM)) inhibits XBP1 splicing (XBP1s) in a dose dependent manner.
3,6-DMAD hydrochloride (0.1-500 μM; 14 h; HT1080 cells treated with Tg (0.3 μM)) inhibits IRE1α endonuclease activity.
3,6-DMAD hydrochloride (1-60 μM; 2 h; HEK293 cells) inhibits IRE1α oligomerization and IRE1α-GFP foci formation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	RPMI 8226 and MM1.R human MM cells
Concentration:	0, 0.5, 1, 2, 3, 4, 5 and 6 μM
Incubation Time:	24 hours
Result:	Inhibited cell survival rate in a dose dependent manner.

Western Blot Analysis

Cell Line:	HT1080 cells treated with Tg (0.3 μM)
Concentration:	0, 5, 10 and 30 μM
Incubation Time:	14 hours
Result:	Showed XBP1s inhibition at as low as 0.5 μM.

体内研究
(In Vivo)

3,6-DMAD hydrochloride (10 mg/kg; i.p.; three times every 12 hours, for 84 hours; NOD Scid mice with RPMI 8226 xenograft) has inhibition of XBP1 splicing in vivo.
3,6-DMAD hydrochloride (10 mg/kg; 24 h; i.p.; every 48 hours, for 12 days; NOD Scid mice with RPMI 8226 xenograft) suppresses multiple myeloma xenograft growth in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD Scid mice (4-6 weeks) with RPMI 8226 xenograft
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; three times every 12 hours, for 84 hours
Result:	Inhibited XBP1-luciferase activity in NOD Scid mice with RPMI 8226 xenograft.

Animal Model:	NOD Scid mice (4-6 weeks) with RPMI 8226 xenograft
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; every 48 hours, for 12 days
Result:	Inhibited tumor growth in NOD Scid mice with RPMI 8226 xenograft.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD Scid mice (4-6 weeks) with RPMI 8226 xenograft
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; three times every 12 hours, for 84 hours
Result:	Inhibited XBP1-luciferase activity in NOD Scid mice with RPMI 8226 xenograft.

Animal Model:	NOD Scid mice (4-6 weeks) with RPMI 8226 xenograft
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; every 48 hours, for 12 days
Result:	Inhibited tumor growth in NOD Scid mice with RPMI 8226 xenograft.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD Scid mice (4-6 weeks) with RPMI 8226 xenograft
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; three times every 12 hours, for 84 hours
Result:	Inhibited XBP1-luciferase activity in NOD Scid mice with RPMI 8226 xenograft.

Animal Model:	NOD Scid mice (4-6 weeks) with RPMI 8226 xenograft
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; every 48 hours, for 12 days
Result:	Inhibited tumor growth in NOD Scid mice with RPMI 8226 xenograft.